Department of Experimental and Clinical Medicine, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy.
Eur Rev Med Pharmacol Sci. 2021 Jul;25(14):4799-4809. doi: 10.26355/eurrev_202107_26393.
Polycystic ovary syndrome (PCOS) is an endo-crine disorder that occurs in 8-10% of women of reproduc-tive age. It is characterized by oligo or anovulation, hyperandrogenism and/or polycystic ovaries, but also by an increased insulin plasma level especially in overweight/obese women or in those with familial diabetes. In the last years, among the insulin sensitizers, the use of the two active isoforms of inositols (myo-inositol and d-chiro-inositol) has been spreading for the treatment of PCOS insulin resistance. Several studies have shown a positive role of inositols both on the metabolic profile of PCOS patients, but also on hormonal parameters. Hence, inositols can positively affect the infertility that characterizes many PCOS patients, acting both on ovarian function and spontaneous ovulation and during IVF procedures, in terms of oocyte quality and pregnancy rate.
多囊卵巢综合征（PCOS）是一种内分泌疾病，发生在 8-10%的育龄妇女中。其特征是排卵减少或无排卵、高雄激素血症和/或多囊卵巢，同时还伴有血浆胰岛素水平升高，尤其是在超重/肥胖或有家族糖尿病的妇女中。近年来，在胰岛素增敏剂中，两种活性形式的肌醇（肌醇和 D-手性肌醇）的使用已被广泛应用于治疗 PCOS 胰岛素抵抗。多项研究表明，肌醇对 PCOS 患者的代谢特征以及激素参数都有积极作用。因此，肌醇可以通过改善卵巢功能和自发排卵，以及提高卵母细胞质量和妊娠率，对许多 PCOS 患者的不孕问题产生积极影响。
